ViThera’s vision is to develop novel drugs based on the ability to engineer microbes – bacteria and yeast to enhance their beneficial properties. This can be achieved through the expression of beneficial protein factors secreted by the therapeutic bacteria (as exemplified in the ENLACT™ system) or through other engineered properties.
Our scientists have developed groundbreaking technologies and tools to enable this research. ViThera’s ENLACT ™ (ENhanced Lactococcus) platform is unique in its ability to express beneficial proteins from therapeutic bacteria inside of the patient’s body. Lactococcus Lactis, a common food bacterium, is reprogrammed to become a safe and diligent manufacturer of anti-inflammatory agents to help control disease such as Crohn’s Disease and Ulcerative Colitis. In its final form ENLACT™ will be administered orally and broaden the therapeutic arsenal for the treatment of Inflammatory Bowel Disease. Patients ingest a dose of ENLACT™ daily in a special therapeutic yoghurt to control their symptoms of cramping, bleeding, and inflammation. ENLACT™ is designed to alter the clinical course of Inflammatory Bowel Disease to allow patients to reduce their dose of other anti-inflammatory drugs (such as steroids, immune modulators, NSAIDs and others).
At the same time, ViThera is making an investment in basic research to explore further innovative uses of the interplay between the gastrointestinal microbiome and our body to modulate health.